Lumida
/APLS
⌘K
Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

APLS
$41.03USD-0.07%-0.03 today

MARKET CAP

5.3B

P/E (TTM)

273.5x

FWD P/E

DAY RANGE

$41 – $41

52W RANGE

$16
$41
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$66.6M$75.4M$396.6M$781.4M$1.0B
YoY %-73.4%+13.3%+425.8%+97.0%+28.5%
P / Sales60.0x70.7x18.3x5.1x3.2x
EV / Sales60.6x71.3x18.9x5.4x3.5x
Gross Profit, Adj.$66.4M$69.8M$338.1M$663.6M$901.5M
YoY %-73.5%+5.2%+384.5%+96.3%+35.8%
Margin %99.7%92.5%85.2%84.9%89.8%
EV / Gross Profit60.8x77.0x22.2x6.3x3.9x
EBITDA, Adj.$-534.9M$-593.1M$-515.3M$-163.2M$57.0M
YoY %-151.0%-10.9%+13.1%+68.3%+134.9%
Margin %-803.6%-786.3%-129.9%-20.9%5.7%
EV / EBITDA-7.5x-9.1x-14.6x-25.7x61.4x
EBIT$-536.3M$-594.6M$-517.1M$-165.0M$55.4M
YoY %-150.9%-10.9%+13.0%+68.1%+133.6%
Margin %-805.7%-788.4%-130.4%-21.1%5.5%
EV / EBIT-7.5x-9.0x-14.5x-25.5x63.2x
Net Income$-746.4M$-652.2M$-528.6M$-197.9M$22.4M
YoY %-116.4%+12.6%+18.9%+62.6%+111.3%
Net Margin-1121.3%-864.7%-133.3%-25.3%2.2%
EPS (GAAP)-$8.84-$6.15-$4.45-$1.60$0.20
YoY %-92.6%+30.4%+27.6%+64.0%+112.5%